Skye Bioscience, Inc. Stock News

Skye Bioscience Inc (OTCQB:SKYE) said it has started screening for its first-in-human Phase 1 trial of SBI-100 Ophthalmic Emulsion (SBI-100 OE), a proprietary, synthetic cannabinoid derivative intend

Skye Bioscience Inc (OTCQB:SKYE) announced that it has concluded the merger with Emerald Health Therapeutics after both companies' shareholders voted in favor and the Supreme Court of British Columbia

Skye Bioscience Inc (OTCQB:SKYE) said it has been advised by its contract manufacturer that it has completed the production of SBI-100 Ophthalmic Emulsion (SBI-100 OE) for Skye's phase one clinical tr

Skye Bioscience Inc (OTCQB:SKYE) has announced that the shareholders of Emerald Health Therapeutics Inc (CSE:EMH, OTCQX:EMHTF) have approved the proposed plan of arrangement which will result in the i

Skye Bioscience Inc (OTCQB:SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, said it has selected NextPharma as its contract manufacturing o

Skye Bioscience inc (OTCQB:SKYE) said completion of the production of its Phase 1 drug has been delayed to the beginning of September 2022 due to a now resolved cyber-attack and planned maintenance s

Skye Bioscience inc (OTCQB:SKYE) has received regulatory approval to begin its first-in-human Phase 1 clinical study of SBI-100 Ophthalmic Emulsion, a patented drug representing a new class of therape

Small companies accessing capital to fund growth mostly have an uphill challenge. With inflation slamming the global economy like a wrecking ball this year, the market mayhem is going to make it even

Skye Bioscience inc (OTCQB:SKYE) said it has signed new research agreements with the University of Eastern Piedmont (UPO) in Italy and the Spanish Research Council (CSIC), focusing on developing an e

San Diego, California--(Newsfile Corp. - June 6, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing proprietary, synthetic cannabinoid derivativ

Skye Bioscience Inc (OTCQB:SKYE) and Emerald Health Therapeutics Inc said they have entered into a definitive agreement that will see Skye acquiring Emerald in a share-for-share transaction. Under th

Skye Bioscience inc (OTCQB:SKYE) announced that the peer-reviewed journal International Journal of Pharmaceutics has published preclinical data demonstrating stronger and longer-lasting reduction of i

Skye Bioscience inc (OTCQB:SKYE) said it has hired experienced Australian clinical trial operator CMAX to run its phase 1 study of lead candidate SBI-100 OE to treat glaucoma in Adelaide with final da

Skye Bioscience inc (OTCQB:SKYE) announced that it has entered into an agreement with Novotech Health Holdings, a leading full-service contract research organization (CRO) in Asia-Pacific, for the upc

Skye Bioscience inc (OTCQB:SKYE) announced that it has completed a good laboratory practice (GLP) nonclinical toxicology study of its SBI-100 ophthalmic nanoemulsion in support of the company's planne